000132855 001__ 132855
000132855 005__ 20240229105035.0
000132855 0247_ $$2doi$$a10.1093/neuonc/nox166
000132855 0247_ $$2pmid$$apmid:29194500
000132855 0247_ $$2pmc$$apmc:PMC5909649
000132855 0247_ $$2ISSN$$a1522-8517
000132855 0247_ $$2ISSN$$a1523-5866
000132855 0247_ $$2altmetric$$aaltmetric:29627857
000132855 037__ $$aDKFZ-2018-00498
000132855 041__ $$aeng
000132855 082__ $$a610
000132855 1001_ $$aRudà, Roberta$$b0
000132855 245__ $$aEANO guidelines for the diagnosis and treatment of ependymal tumors.
000132855 260__ $$aOxford$$bOxford Univ. Press$$c2018
000132855 3367_ $$2DRIVER$$aarticle
000132855 3367_ $$2DataCite$$aOutput Types/Journal article
000132855 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660124075_27718$$xReview Article
000132855 3367_ $$2BibTeX$$aARTICLE
000132855 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132855 3367_ $$00$$2EndNote$$aJournal Article
000132855 520__ $$aEpendymal tumors are rare CNS tumors and may occur at any age, but their proportion among primary brain tumors is highest in children and young adults. Thus, the level of evidence of diagnostic and therapeutic interventions is higher in the pediatric compared with the adult patient population.The diagnosis and disease staging is performed by craniospinal MRI. Tumor classification is achieved by histological and molecular diagnostic assessment of tissue specimens according to the World Health Organization (WHO) classification 2016. Surgery is the crucial initial treatment in both children and adults. In pediatric patients with intracranial ependymomas of WHO grades II or III, surgery is followed by local radiotherapy regardless of residual tumor volume. In adults, radiotherapy is employed in patients with anaplastic ependymoma WHO grade III, and in case of incomplete resection of WHO grade II ependymoma. Chemotherapy alone is reserved for young children <12 months and for adults with recurrent disease when further surgery and irradiation are no longer feasible. A gross total resection is the mainstay of treatment in spinal ependymomas, and radiotherapy is reserved for incompletely resected tumors. Nine subgroups of ependymal tumors across different anatomical compartments (supratentorial, posterior fossa, spinal) and patient ages have been identified with distinct genetic and epigenetic alterations, and with distinct outcomes. These findings may lead to more precise diagnostic and prognostic assessments, molecular subgroup-adapted therapies, and eventually new recommendations pending validation in prospective studies.
000132855 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000132855 588__ $$aDataset connected to CrossRef, PubMed,
000132855 7001_ $$0P:(DE-HGF)0$$aReifenberger, Guido$$b1
000132855 7001_ $$aFrappaz, Didier$$b2
000132855 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b3
000132855 7001_ $$aLaprie, Anne$$b4
000132855 7001_ $$aSantarius, Thomas$$b5
000132855 7001_ $$aRoth, Patrick$$b6
000132855 7001_ $$0P:(DE-HGF)0$$aTonn, Joerg Christian$$b7
000132855 7001_ $$aSoffietti, Riccardo$$b8
000132855 7001_ $$0P:(DE-HGF)0$$aWeller, Michael$$b9
000132855 7001_ $$aMoyal, Elizabeth Cohen-Jonathan$$b10
000132855 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox166$$gVol. 20, no. 4, p. 445 - 456$$n4$$p445 - 456$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000132855 909CO $$ooai:inrepo02.dkfz.de:132855$$pVDB
000132855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132855 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000132855 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$aExternal Institute$$b9$$kExtern
000132855 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000132855 9141_ $$y2018
000132855 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000132855 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132855 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000132855 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132855 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132855 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132855 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132855 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132855 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132855 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132855 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000132855 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x0
000132855 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000132855 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132855 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x3
000132855 980__ $$ajournal
000132855 980__ $$aVDB
000132855 980__ $$aI:(DE-He78)L401-20160331
000132855 980__ $$aI:(DE-He78)B062-20160331
000132855 980__ $$aI:(DE-He78)L101-20160331
000132855 980__ $$aI:(DE-He78)L701-20160331
000132855 980__ $$aUNRESTRICTED